Drug Profile
PRAX 330
Alternative Names: GS967; PRAX-330Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Praxis Precision Medicines
- Developer Northwestern University Feinberg School of Medicine; Praxis Precision Medicines
- Class Antiepileptic drugs; Neuroprotectants; Pyridines; Small molecules; Triazoles
- Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Epilepsy in USA (PO, Suspension)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in Australia (PO, Suspension)
- 10 Nov 2018 Praxis Precision Medicines completes a phase I trial in Epilepsy (In volunteers) in Australia (ACTRN12617001512314)